Neko Health has raised $700 million to expand its AI body scans in the United States, starting with a clinic in New York. The company's preventive screening service combines medical imaging, blood tests, proprietary sensors, and clinician review. This expansion will allow Neko Health to further test and refine its AI technology for detecting cancer at an early stage.
The Series C round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Existing investors also participated in the funding round. With this investment, Neko Health plans to accelerate its research and development efforts, focusing on improving the accuracy of its scans and expanding its service offerings.
The company's AI technology is designed to provide a more comprehensive understanding of a person's health, enabling doctors to detect cancer earlier and potentially saving lives. By leveraging machine learning algorithms and advanced medical imaging techniques, Neko Health aims to revolutionize personalized cancer detection in the US.